Year: 2019

Engineering Adoptive T Cell Therapy for Efficacy in Ovarian Cancer

In this project, we want to specifically boost antitumor immune responses. Immune “T” cells can selectively kill abnormal cells, and some of a patient’s own T cells may be able to recognize and kill cancer cells naturally…

Read on

Investigating Regulators of Quiescence in Epithelial Ovarian Cancer

Epithelial Ovarian Cancer (EOC) is the fifth most common cause of cancer-related death in American women with the third highest mortality:incidence ratio. One reason for the high mortality rate is the development of resistance to anti-cancer drugs…

Read on

Modeling Autologous TIL Therapy in Novel PARP Resistant PDX Model for Ovarian Cancer

With only a 46 percent 5-year survival rate, ovarian cancer is the most lethal of all gynecological malignancies. High grade serous ovarian cancers (HGSOC) are the most common type of ovarian cancer…

Read on

Therapeutic miRNA Targeting for Ovarian Cancer

This project proposes a novel treatment approach in OC. Having previously identified miR-517 as a key regulator of OC, we now aim to test the pre-clinical potential of this strategy and potentially uncover new molecular circuits involved in OC…

Read on

Transcriptional Regulatory Landscape of High Grade Serous Ovarian Cancer

Ovarian cancer is the leading cause of gynecologic cancer death in the United States, responsible for over 22,000 cases per year and over 14,000 deaths. The most common type of ovarian cancer is High Grade Serous Ovarian Cancer (HGSOC)…

Read on

Examining the Role of RNF168 in BRCA1 Mutant Ovarian Cancer

Hereditary mutations in the BRCA1 gene predispose carriers to ovarian cancer…

Read on

Synergistic Lethality of PARP and P13K Pathway Inhibitors in Ovarian Cancer

Ovarian cancer (OC) is the deadliest gynecological cancer with an overall survival of less than 40%…

Read on

ARID1A Drives Ovarian Cancer Immunotherapy

Ovarian clear cell carcinoma (OCCC) carries the worst prognosis across all ovarian cancer subtypes…

Read on

Cyclin E and BRD4 as Markers for a New PARPi Drug Combination

Ovarian Cancer is the deadliest gynecologic cancer in the United States. Treatment options for women diagnosed with ovarian cancer have recently expanded to include Poly ADP ribose polymerase (PARP) inhibitors…

Read on

Targeting MISIIR with CAR T Cells for the Treatment of Ovarian Cancer

Ovarian cancer ranks 5th among cancer-related deaths in women and is the most lethal of all gynecologic malignancies, with an overall 5-year survival rate of 46%. Therefore, there is a dire need for effective therapies…

Read on

Re-activating Anti-tumor Immunity Targeting PSEN1 in CAFS in Ovarian Cancer

Immunotherapy is increasingly recognized as an important therapeutic strategy for many cancers…

Read on

Synthetic Lethality for ARID1A Mutation in Ovarian Cancer

Epithelial ovarian cancer (EOC), which accounts for about 90% of ovarian cancers, is the most lethal gynecological malignancy in the United States…

Read on